• Vir Biotechnology Inc VIR.OQ reported a quarterly adjusted loss of 76 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -86 cents. The mean expectation of eight analysts for the quarter was for a loss of 87 cents per share. Wall Street expected results to range from -96 cents to -66 cents per share.

• Revenue fell 26.3% to $12.37 million from a year ago; analysts expected $8.14 million.

• Vir Biotechnology Inc's reported EPS for the quarter was a loss of 76 cents​.

• The company reported a quarterly loss of $104.59 million.

• Vir Biotechnology Inc shares had risen by 24.0% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Vir Biotechnology Inc is $20.00

This summary was machine generated from LSEG data February 26 at 11:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)